32
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Effect of Prior Nucleoside Use on the Two-Year Virological Response to an Initial Protease Inhibitor Regimen in HIV-Infected Patients

, , &
Pages 213-218 | Published online: 29 Jan 2015

REFERENCES

  • Clendeninn N, Quart B, Anderson R, Knowles M, Chang Y. Analysis of long-term virologic data from the Viracept (Nelfinavir, NFV) 511 protocol using three HIV-RNA assays. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; 1998; Chicago, IL. Abstract 372.
  • Gulick RM, Mellors JW, Haylir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337(11):734–739.
  • Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11(14):F113–F116.
  • Brett G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS. 1998;12(16):2193–2202.
  • Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 1999;13(3):367–373.
  • Wit RN, van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy: One year follow-up of a cohort of human immunodefi-ciency virus type 1-infected persons. J Infect Dis. 1999;179(4):790–798.
  • Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12(16): 2161–2167.
  • Moyle G. Saquinavir: A review of its development, pharma-cological properties and clinical use. Exp Invest Drugs. 1996;5:155–157.
  • Tsoukas C, Reddy DA, et al. Predictive value of response at 12 and 24 weeks for durability of response in a study of the soft gelatin capsule formulation of saquinavir (SQV-SGC) plus two nucleosides in treatment-naïve HIV-1-positive pa-tients. In: Program and abstracts from the Sixth Confer-ence on Retroviruses and Opportunistic Infections; 1999; Chicago, IL. Abstract 165.
  • Easterbrook PJ, Newson R, Ives NJ, Gazzard B. Predictors of virologic response and subsequent failure to five differ-ent initial protease inhibitor treatment regimens. In: Pro-gram and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; 1999; Chicago, IL. Abstract 171.
  • Weidle PJ, Lichtenstein KA, Moorman AC, et al. Factors associated with the successful modification of antiretroviral therapy. Abstracts of the IDSA 36th Annual Meeting, 1998; San Francisco, CA: 1005.
  • Albrecht M, Katzenstein D, Bosch R, et al. ACTG 364: Virologic efficacy of nelfinavir (NR/) and or efavirenz (EFZ) in combination with new nucleoside analogs in nucleoside experienced subjects. In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infec-tions; 1999; Chicago, IL. Abstract 489.
  • Gomez-Cano G, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-in-fected patients in Spain. AIDS. 1998;12(9):1015–1020.
  • Larder B. New insights into genetic mechanisms of HIV drug resistance. In: Program and abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections; 1999; Chicago, IL. Abstract S34.
  • Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults; updated recommendations of the Inter-national AIDS Society-USA Panel. JAMA. 2000;283:381–390.
  • Guidelines for the Use of Antiretroviral Agents in HIV-In-fected Adults and Adolescents. Department of Health and Human Services (DHHS). Available at: http://www.hivatis.org.
  • Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial. Lancet. 1999;353:2195–2199.
  • Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma geno-typic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Com-munity Programs for Clinical Research on AIDS. AIDS. 2000;14(9):F83–F93.
  • Demeter L. Drug resistance and the management of treat-ment failure. In: Program and abstracts of the Seventh Con-ference on Retroviruses and Opportunistic Infections; Janu-ary 30-February 2, 2000; San Francisco, CA. Abstract S32.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.